These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Secrets of the HIV controllers: A rare group of HIV-positive individuals need no medicine to keep the virus in check. Their good fortune could point the way to more powerful treatments--and perhaps a vaccine. Walker BD Sci Am; 2012 Jul; 307(1):44-51. PubMed ID: 22779271 [No Abstract] [Full Text] [Related]
24. Immune responses in asymptomatic HIV-1-infected patients after HIV-DNA immunization followed by highly active antiretroviral treatment. Calarota SA; Leandersson AC; Bratt G; Hinkula J; Klinman DM; Weinhold KJ; Sandström E; Wahren B J Immunol; 1999 Aug; 163(4):2330-8. PubMed ID: 10438897 [TBL] [Abstract][Full Text] [Related]
25. Can HIV be cured? Stevenson M Sci Am; 2008 Nov; 299(5):78-83. PubMed ID: 18998350 [No Abstract] [Full Text] [Related]
26. Immune activation and the pathogenesis of HIV disease: implications for therapy. Fernandez S; Lim A; French M J HIV Ther; 2009 Nov; 14(3):52-6. PubMed ID: 20218239 [No Abstract] [Full Text] [Related]
27. Correlates of cytotoxic T-lymphocyte-mediated virus control: implications for immunosuppressive infections and their treatment. Wodarz D; Nowak MA Philos Trans R Soc Lond B Biol Sci; 2000 Aug; 355(1400):1059-70. PubMed ID: 11186307 [TBL] [Abstract][Full Text] [Related]
28. Predicting the potential impact of a cytotoxic T-lymphocyte HIV vaccine: how often should you vaccinate and how strong should the vaccine be? Smith RJ; Schwartz EJ Math Biosci; 2008 Apr; 212(2):180-7. PubMed ID: 18359048 [TBL] [Abstract][Full Text] [Related]
29. Trial suggests vaccines could aid HIV therapy. Check E Nature; 2003 Apr; 422(6933):650. PubMed ID: 12700722 [No Abstract] [Full Text] [Related]
30. Highly active antiretroviral therapy leads to a significant but delayed increase of CD45RA+ T-helper cells. Degen O; Stellbrink HJ; Lauer J; van Lunzen J AIDS; 1998 Sep; 12(13):1715-6. PubMed ID: 9764793 [No Abstract] [Full Text] [Related]
31. Cure of HIV infection: is the long wait over? Shearer WT J Allergy Clin Immunol; 2014 Jul; 134(1):20-2. PubMed ID: 25117800 [No Abstract] [Full Text] [Related]
32. Restoring HIV-specific immunity. James JS AIDS Treat News; 1999 Feb; (No 312):2-6. PubMed ID: 11366200 [TBL] [Abstract][Full Text] [Related]
33. The cellular immune response to the human immunodeficiency virus. Rivière Y Curr Opin Immunol; 1989-1990 Feb; 2(3):424-7. PubMed ID: 2576771 [No Abstract] [Full Text] [Related]
34. Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia. Rosenberg ES; Billingsley JM; Caliendo AM; Boswell SL; Sax PE; Kalams SA; Walker BD Science; 1997 Nov; 278(5342):1447-50. PubMed ID: 9367954 [TBL] [Abstract][Full Text] [Related]
35. AIDS researchers negotiate tricky slopes of science. Balter M Science; 1998 May; 280(5365):825-6. PubMed ID: 9599153 [No Abstract] [Full Text] [Related]
36. Preparing for HIV vaccines that induce cytotoxic T lymphocytes. McMichael A Curr Opin Immunol; 1998 Aug; 10(4):379-81. PubMed ID: 9722911 [No Abstract] [Full Text] [Related]
37. The critical need for CD4 help in maintaining effective cytotoxic T lymphocyte responses. Kalams SA; Walker BD J Exp Med; 1998 Dec; 188(12):2199-204. PubMed ID: 9858506 [No Abstract] [Full Text] [Related]